BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing
Reuters
Oct 14, 2025
BioCryst Pharmaceuticals to Acquire Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Expanding HAE Portfolio and Securing Strategic Financing
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from Blackstone.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545075-en) on October 14, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.